Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04739059 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
NCT04739059 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 171 participants.
The verdict
NCT04739059, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
Study Summary
This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)
Interventions
- BIOLOGICAL CSL312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2025-11-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04739059
The ClinicalTrials.gov registry entry for NCT04739059 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CSL312 is the first listed.
NCT04739059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04739059 about?
NCT04739059 is a clinical study titled "Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks". This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)
What is the current status of trial NCT04739059?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2021-03-29. Estimated completion is 2025-11-21.
What interventions are being tested in trial NCT04739059?
The interventions under investigation include: CSL312 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04739059?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.